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Abstract The current epidemic of obesity in western
countries is being worsened by the lack of effective pharma-
cotherapies. The apparent success of a central nervous system-
acting cannabinoid CB1 receptor antagonist-based treatment
for obesity was hampered by the appearance of psychiatric
side effects in certain patients. These adverse effects forced its
withdrawal from the market. However, the discovery that the
main beneficial metabolic effects of cannabinoid CB1 receptor
antagonists were derived of its activity in peripheral tissues,
including the adipose tissue, opened the possibility of rescuing
this type of therapy. This goal might be achieved by differen-
tial medicinal chemistry approaches. The present review
examines these options that include peripheral-restricted can-
nabinoid CB1 receptor antagonists, dual ligands and combi-
natorial therapies using sub-effective doses of CB1 receptor
antagonists that might be devoid of side effects.
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Introduction
In the last few decades, the incidence of overweight and
obesity has grown to epidemic proportions. Obesity is a
complex metabolic disorder characterized by an imbalance
in energy homeostasis, abnormal increase of adipose tissue,
and dysregulation of hormones, cytokines and other impor-
tant signaling systems. This multi-factorial disorder is asso-
ciated with co-morbidities such as cardiovascular risk,
hypertension, sleep apnea, diabetes mellitus, hepatic steato-
sis and certain types of cancer among others. Its impact on
national health systems has led to substantial research
efforts towards the discovery of novel anti-obesity therapies.
Among the new targets for pharmaceutical development
of anti-obesity drugs, the endogenous cannabinoid system
(ECS) remains a focus of attention. This signaling system is
widely distributed in the central nervous system and periph-
eral tissues, and is involved in physiological actions related
to food intake and energy homeostasis, predominantly via
the cannabinoid type 1 receptor (CB1). Animal studies and
clinical trials have shown that blockade of CB1 receptor
induces weight loss, improves cardiometabolic risk factors
and insulin resistance, and causes metabolic benefits. There-
fore, all these data have emphasized the potential of CB1
receptor blockade as a therapeutic strategy in obesity.
Following this rationale, several cannabinoid receptors
antagonists have been developed and some of them have
reached clinical trials. One of them, rimonabant, eventually
reached the market after approval by the European Medi-
cines Agency. Nevertheless, the central actions of the pro-
totypic CB1 receptor antagonist rimonabant have also been
associated with the appearance, in clinical trials, of adverse
psychiatric side effects, such as anxiety and depression, in
patients treated for obesity. These adverse effects have
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motivated the withdrawal of rimonabant from the market.
However, the question remains whether peripheral blockade
of CB1 receptors is still an acceptable mechanism/strategy
for the treatment of obesity. The aim of this review is
twofold: to summarize the effects of CB1 receptor blockade
in energy balance and to discuss the development of new
approaches for obesity as effective therapies with reduced
side effects.
The Endogenous Cannabinoid System
The ECS is a physiological signaling system which com-
prises cannabinoid receptors, endogenous ligands and
enzymes responsible for the synthesis, transport and inacti-
vation of these ligands [1•]. The best characterized endoge-
nous cannabinoids are N-arachidonoylethanolamine (also
known as anandamide, AEA) and 2-arachidonoylglycerol
(2-AG), both derived from arachidonic acid conjugated with
ethanolamine or glycerol, respectively [2–4]. Although
AEA and 2-AG were originally identified as synaptic neuro-
modulators in neuronal systems, endocannabinoids are im-
plicated in the regulation of several physiological processes
in other non-nervous tissues. Therefore, endocannabinoids
are present in brain, plasma, and peripheral tissues exerting
agonist activity at cannabinoid receptors.
Two major types of cannabinoid receptors have been
characterized and cloned: CB1 and CB2, both of which
belong to the super-family of G protein-coupled receptors.
While CB1 receptors are highly expressed in brain and are
also found in peripheral tissues (e.g. muscle, gastrointestinal
tract, pancreas, liver and adipose tissue) [5–8], CB2 recep-
tors are mainly located in immune cells (T cells, B cells and
monocytes) although there is evidence for their expression
in both neurons and glial cells in the brain [9, 10]. In
addition to classical cannabinoid receptors, other targets
have been found to be modulated by endocannabinoids
including the transient receptor potential vanilloid type 1
channel and orphan G protein-coupled receptors, such as
GPR55 [11•].
Endocannabinoids are not stored in cellular vesicles, but
are produced on demand, and rapidly degraded by intracel-
lular enzymes; thus, the importance of the enzymes involved
in their synthesis and degradation. The major route for AEA
production is from phospholipid precursors through the
action of N-acylphosphatidylethanolamine-selective phos-
pholipase D (NAPE-PLD) [12], while 2-AG derives primar-
ily from the hydrolytic metabolism of 1,2-diacylglycerol
(DAG) mediated by two sn-1-selective DAG lipases,
DAGLα and DAGLβ [13]. Inactivation of the endocannabi-
noid signaling is mediated by cellular reuptake and subse-
quent intracellular hydrolysis. Fatty acid amide hydrolase
(FAAH) and monoacylglycerol lipase (MAGL) have been
identified as enzymes primarily responsible for the degrada-
tion of AEA and 2-AG, respectively [14, 15]. Additional
metabolic pathways have been described using specific mo-
lecular inhibitors and genetic models lacking particular
enzymes [16].
The ECS in Obesity
The widespread presence of the ECS indicates its physio-
logical relevance in the regulation of a variety of biological
processes (e.g. modulation of neural development, immune
function, synaptic plasticity and learning, emotional state,
pain…). In recent years, there has been substantial interest
in investigating the role of endocannabinoid signaling in the
regulation of metabolism and energy homeostasis, mainly
due to the abundance of CB1 receptor expression in brain
regions and peripheral tissues involved in the control of
feeding behavior and energy balance. CB1 receptors, as well
as endocannabinoid producing machinery have been de-
scribed in the gut [17], liver [18], muscle [19•], endocrine
pancreas [20] and white adipose tissue [21, 22]. In this
regard, it is well known that activation of CB1 receptors
promotes appetite and weight gain, while its blockade indu-
ces anorexia and weight loss with metabolic effects in
mammals [23•].
Obesity is characterized by leptin and insulin resistance,
and appears to be associated with a dysregulated and hyper-
active ECS in rodents and humans. There is an increase in
circulating endocannabinoid levels and altered expression of
the components of this system in cerebral areas such as
hypothalamus, hindbrain and limbic areas, but also in periph-
eral organs including adipose tissue, liver and pancreas [24].
In fact, diet-induced obese mice display an up-regulation
of the components of the ECS in the hypothalamus and in
other extrahypothalamic areas, such as the hippocampus and
the extended amygdala, brain areas involved in the emo-
tional aspects of eating [25, 26, 27•]. Similarly, high levels
of endocannabinoids have been found in the hypothalamus
of rodents, with an altered leptin signaling, such as db/db
and ob/ob mice or Zucker fa/fa rats, which can be consid-
ered genetic models of obesity. This may be due to the fact
that the biosynthesis of hypothalamic endocannabinoids is
under the negative control of functional leptin [28].
In peripheral tissues and plasma, elevated endocannabi-
noid levels have also been found in obese compared to lean
subjects. Recent clinical studies have shown that obesity is
associated with elevated levels of 2-AG in visceral fat, a
tissue that plays a main role in the development of metabolic
syndrome, showing a positive correlation between visceral
fat accumulation and circulating level of 2-AG. Interesting-
ly, patients with type-2 diabetes have increased endocanna-
binoid levels in plasma [29, 30]. However, these elevations
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in endocannabinoids have also been reported in other feed-
ing disorders such as anorexia nervosa and binge eating
disorders. In all these cases, the elevated levels may be
secondary to low levels of circulating leptin [31]. A recent
study in healthy normal weight subjects has also demon-
strated gender differences for endocannabinoids in plasma.
Indeed, circulating levels of 2-AG are higher in males com-
pared with females, as well as the existence of a strong
correlation between 2-AG and triglyceride levels. In
females, by contrast, these authors have observed an asso-
ciation between circulating AEA and adiposity and meta-
bolic parameters [32•].
The increase in endocannabinoids may be caused by
alterations in other enzymes related to the ECS. For in-
stance, increased endocannabinoid levels may be due to
the inhibition of the endocannabinoid-degrading enzyme
FAAH, since a down-regulation of its gene expression and
a decrease of its activity in adipose tissue and liver has been
reported [18, 33]. Another recent clinical study has sug-
gested that the dysregulation of ECS may result from a
genetic predisposition. In this study, a significant association
between a missense polymorphism in FAAH that leads to
decreased enzymatic activity and overweight/obesity has
been found [34]. Insulin might participate in such enzymatic
regulation, since it has been reported that insulin decreases
endocannabinoid levels and stimulates FAAH expression in
adipose tissue of non-obese subjects, and therefore elevated
endocannabinoid levels in obesity may also be due to insulin
resistance [35].
In addition, the expression of CB1 receptors is also altered
in obesity. In fact, increased concentrations of endocannabi-
noids may overstimulate CB1 receptors in a pathophysiolog-
ical manner contributing to obesity [24, 29, 33, 36, 37].
However, the dysregulation of the CB1 receptor observed in
peripheral organs is diverse throughout different animal stud-
ies and clinical trials with both elevations and reductions of its
gene expression. Obese rodents display an increased CB1
gene expression in adipose tissue, liver and skeletal muscle
[18, 38, 39] and such increased expression has also been
observed in adipose tissue in human obesity [35, 40]. How-
ever, other studies reported no changes in CB1 gene expres-
sion in visceral and subcutaneous adipose tissue, or even
reduced CB1 expression with obesity [33, 41]. This alteration
of CB1 receptors has also been detected in the brain and, for
instance, Zucker obese rats display a higher CB1 receptor
binding than their lean counterparts in limbic regions, includ-
ing reward-related brain areas that may contribute to hyper-
phagia [42].
Classical studies using cannabinoid CB1 receptor block-
ers show a more effective effect in obese rodents than in lean
controls [38, 43, 44, 45•]. This increased sensitivity of obese
animals can be explained by a higher sensitivity to the
effects of CB1 antagonists due to the dysregulation and
overactivation of the ECS. Another alternative explanation
is related to the inverse agonism activity exhibited by these
CB1 receptor blockers. However, CB1 receptor blockers
identified as neutral CB1 antagonists have been reported to
produce comparable metabolic benefits [46•].
Accordingly, pharmacological blockade of CB1 signaling
represents an interesting approach for the development of
new therapies against obesity. Consequently, several CB1
receptor antagonists and inverse agonists have been devel-
oped as anti-obesity drugs in recent years.
Central Versus Peripheral CB1 Receptor Blockade
in Obesity: The Pros and Cons
Although early studies were focused on the ECS located in
central nervous system circuits which regulate appetite and
food intake, a growing body of evidence indicates that these
functions are modulated through a combination of both
central and peripheral mechanisms. CB1 receptor activation
results in increased appetite [47, 48] and, although these
receptors are highly expressed in cerebral areas involved in
the regulation of motivated behaviors, they are also found in
peripheral tissues with important functions related to the
maintenance of energy balance. Thus, genetically modified
mice lacking CB1 receptors eat less than wild-type litter-
mates, even under fasting conditions. They show decreased
body weight and reduced fat content compared to their
controls, and are resistant to high-fat diet obesity [21, 28,
49]. Moreover, a continuous stimulation of CB1 receptors
due to elevated levels of endocannabinoids leads to weight
gain, enhancement of adiposity and a gradual worsening of
cardiometabolic risk, and such a scenario is exactly ob-
served in obesity with a dysregulated ECS.
Consequently, several cannabinoid CB1 receptor antago-
nists have been developed as anti-obesity drugs. Synthetic
and plant-derived cannabinoid CB1 receptor blockers have
been reported to suppress food intake, whereas chronic
treatment leads to weight loss and improved metabolic
profile in rodents including both genetic and dietary models
of obesity [43, 44, 50, 51]. CB1 blockers have become a
useful tool for the pharmacological characterization and for
the elucidation of the molecular mechanism of action of the
endocannabinoid signaling pathway.
The first selective CB1 receptor blocker, rimonabant (also
referred to as SR141716A), is a diaryl-pyrazole derivative
which has led to the development of several series of CB1
receptor antagonists/inverse agonists based on its structure
and pharmacological properties (e.g. AM251 and surinabant)
[52]. In addition, other non-diaryl-pyrazole derivatives have
been evaluated in feeding behavior (e.g. taranabant) [53].
Animal studies and human trials, including obese sub-
jects, have proven the efficacy of rimonabant in preventing
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cannabinoid effects as well as its efficacy as anorectic drug.
Studies in animal models of obesity have evidenced that
treatment with rimonabant results in body weight loss result-
ing attributable to a reduction in food intake, but also to an
increase in whole-body energy expenditure with the in-
volvement of several peripheral organs. Blockade of central
and peripheral CB1 receptors by rimonabant has been shown
to induce important weight loss and improvement in several
metabolic parameters correcting hyperinsulinemia, lowering
non-esterified ‘free’ fatty acid levels and reversing insulin
resistance, all of which counteract the adverse effects of an
overstimulated ECS [43, 44].
Central CB1 Receptor Blockade
The central blockade of cannabinoid receptors results in a
significant inhibition of food intake in obese rats mainly
through the CB1 receptor site in the hypothalamus, includ-
ing ventromedial nucleus and lateral hypothalamus, and
other interconnected cerebral areas [54]. Although the ex-
pression of CB1 receptor is not too high in the hypothala-
mus, it is more efficient than in other areas [55, 56].
Interestingly, systemic but not intracerebroventricular ad-
ministration of CB1 antagonists blocks the food intake in
food-deprived animals, suggesting the existence of a periph-
eral mechanism in the modulation of feeding [57]. However,
local administration in determined brain areas blocks these
actions. Indeed, conditional mutant mice characterized by a
CB1 deletion in glutamatergic forebrain-projecting neurons
in the hypothalamus and in the nucleus of the solitary tract
are resistant to diet-induced obesity. Moreover, the treatment
with rimonabant has no effect on body weight and food
intake in these mutant mice [58•]. In this regard, a tolerance
to suppressing-appetite effects has been observed in preclin-
ical studies after chronic CB1 blockade, but not to the effect
on body weight. This differential activity suggests certain
independent mechanisms between food intake and body
weight, which may be explained through opposite actions
of the ECS in glutamatergic and GABAergic neurotransmis-
sion related to food intake [46•, 59•]. Because there is a
bimodal action of CB1 receptor depending on its localiza-
tion on GABA versus glutamatergic receptors, we cannot
attribute feeding reduction to central effects exclusively.
A growing body of evidence suggests an interaction
between the ECS and other orexigenic signals at the hypo-
thalamic level, such as ghrelin and orexin systems. Thus, the
ECS may be able to potentiate the stimulation of appetite
process induced by these signaling systems. By contrast,
both the genetic lack and pharmacological blockade of
CB1 receptors eliminate these orexigenic effects [60–63].
Other polypeptide hormones in the hypothalamus are affect-
ed by endocannabinoid components; in fact, CB1 receptor
knockout mice display altered levels of corticotropin-
releasing hormone and cocaine- and amphetamine-related
transcript [21]. In addition, another study has reported that
treatment with rimonabant is also associated with an altered
leptin signaling in the hypothalamus [64].
It is known that the hypothalamus is interconnected with
the neuronal pathways of the reward system and that can-
nabinoids increase the intake of palatable food [48, 65, 66],
implying a role in the modulation of brain reward mecha-
nisms. The ECS has been reported in limbic areas, such as
nucleus accumbens, ventral tegmental area, amygdala or
prefrontal cortex suggesting an interaction with other sig-
naling systems of neurotransmitters involved in feeding
behavior, such as excitatory glutamate and inhibitory
GABA transmissions and monoaminergic systems, mainly
dopamine and serotonin [59•]. Although not fully explored,
it is therefore reasonable to assume that such an influence
results from interactions between the cannabinoid, opioid
and dopamine systems in the regulation of palatable food
consumption and reward [67–69]. In fact, rimonabant and
other CB1 antagonists can cause comparable dose-
dependent reductions in the consumption of both regular
laboratory chow and palatable diets [70, 71]. However,
CB1 receptor knockout mice do not display phenotypic
differences in sucrose or food consumption [72, 73].
Peripheral CB1 Receptor Blockade
Despite the central mechanisms for the regulation of food
intake by the ECS, there is evidence for the existence of
peripheral mechanisms. Gomez and colleagues have de-
scribed that rimonabant is able to reduce food intake after
peripheral but not central administration in food-deprived
rats, and sensory deafferentation by capsaicin prevents these
peripheral actions on feeding [57]. These results suggest a
main role of CB1 receptors at peripheral sensory nerve
terminals, although central mechanisms are necessary to
exert its actions. Consistent with this study, rimonabant
has been reported to activate c-fos expression in brainstem
receiving vagal inputs after systemic administration in rats
[74•]. Therefore, the presence of cannabinoid receptors in
peripheral organs has to perform additional short-term and
long-term roles in appetite and metabolic changes/adapta-
tions. In fact, the reduction of body weight (gain) and
metabolic benefits by chronic treatment with CB1 blockers
is more probable to be explained by peripheral than by
central effects, at least, in rodent models of obesity [49].
Gastrointestinal Tract It has been demonstrated that the
level of endocannabinoids in the intestinal tract is short-
term modulated by feeding status, with elevated levels fol-
lowing food deprivation and decreases during re-feeding in
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rats [57]. In addition, diet composition also modifies intes-
tinal endocannabinoid levels and a fat-rich meal increases 2-
AG and AEA levels [75]. By contrast, intestinal CB1 recep-
tor blockade by rimonabant reduces fat intake in sham fed
rats (experimental procedure by which animals receive the
diet by a chronically implanted gastric cannula) [76•]. These
results suggest a role of the ECS in the rewarding properties
of fat-rich meals, driving to fat intake from the gastrointes-
tinal tract. Besides, CB1 receptors present on enteric nerves
throughout the wall of the gut are involved in the regulation
of gastrointestinal motility in normal conditions, but such
motility and secretion in the small intestine and the colon
may be affected under pathophysiological conditions. Inter-
estingly, CB1 inverse agonists and neutral antagonists have
different effects on intestinal motility in mice, with a re-
duced gut transit observed only after rimonabant treatment.
Dysregulated and overactivated ECS may be affecting the
regular intestinal transit, which is related to eating disorders
and gut side effects [77].
Liver Initially, the presence of CB1 receptors in the mouse
liver was confirmed indicating that hepatocytes could be a
peripheral molecular target of the ECS [18]. Indeed, the acti-
vation of CB1 receptor increases the expression of lipogenic
genes in the liver, which is the main source of de novo fatty
acid synthesis in the body, and a pretreatment with CB1 recep-
tor antagonists prevents this effect. Moreover, the basal rates of
fatty acid synthesis and triglyceride storage are markedly in-
creased in mice fed a high-fat diet, but not in CB1 knockout
mice, which are resistant to the steatosis effect [18]. The
pretreatment of these mice with a CB1 receptor antagonist
reduces the rate of hepatic fatty acid synthesis, and, therefore,
these data suggest the involvement of cannabinoid activation
in liver steatosis associated with obesity [46•].
Skeletal Muscle Growing evidence indicates that the ECS is
involved in the regulation of glucose uptake and fatty acid
oxidation pathways in skeletal muscle. CB1 receptors are
found in human and rodent skeletal muscle and their con-
tinuous activation by high levels of endocannabinoids is
associated with insulin resistance and with a decrease in
glucose uptake by skeletal muscle cells [22, 78]. By con-
trast, several studies have reported a direct effect of CB1
blockade on energy expenditure and oxidative metabolism
in skeletal muscle. Cavuoto and colleagues have shown that
treatment with rimonabant affects the expression of genes
involved in oxidative metabolism [79]. Therefore, CB1 re-
ceptor antagonists increase the glucose uptake in isolated
soleus muscle of genetically obese mice and in cultured L6
skeletal muscle cells through the phosphatidylinositol-3-
kinase pathway [39, 80]. Recently, it has been described
an altered endocannabinoid signaling in muscle, as a result
of a high-fat diet, and how the blockade of CB1 receptors
could work towards restoration of the metabolic adaption
imposed by diet [19•].
Adipose Tissue While the effects of CB1 receptor blockers
on food intake are transient, the body weight loss or gain
inhibition is sustained over time. For this reason, the addi-
tional peripheral metabolic mechanisms have been proposed
for the anti-obesity effects of this antagonism mainly in
adipose tissue. CB1 receptors were initially found in epidid-
ymal fat pads and subsequently in other adipose tissues, and
their activation in primary adipocytes from mice induced
lipogenesis [21]. Therefore, the blockade of CB1 receptors
in adipocyte is associated with an enhancement of lipid
mobilization and a reduction of lipid storage, contributing
to sustained weight loss [54]. Interestingly, in vivo studies
and in adipocyte cultures treated with rimonabant result in
an increase of adiponectin release, an adipokine involved in
body weight regulation and homeostasis which is secreted
by adipose tissue with plasma levels negatively correlated
with obesity [81]. Another study using obese Zucker rats
has also shown that rimonabant stimulates adiponectin ex-
pression [38]. Accordingly, in vivo studies with obese mice
have demonstrated an improvement of the metabolic syn-
drome associated to obesity after systemic treatment with
rimonabant by reducing the level of insulin, leptin and free
fatty acids [43]. These effects are mediated via CB1 recep-
tors since rimonabant has no effect on adiposity and plasma
insulin levels in CB1 receptor knockout mice [49].
Endocrine Pancreas It is now established the existence of a
functional ECS in the endocrine pancreas, suggesting it as a
potential site for endocannabinoid regulation of glucose
homeostasis. Previous studies have described the presence
of both CB1 and CB2 receptors in rodent pancreatic β- and
non-β-cells [37, 82, 83]. Similarly, human islets of Langer-
hans also express cannabinoid receptors as well as the
machinery involved in synthesis and degradation of 2-AG
[20]. Several lines of evidence suggest that the ECS plays a
role in the regulation of insulin secretion. In fact, in vitro
studies have revealed that the activation of CB1 receptors
stimulates insulin and glucagon secretion [20, 84]. By con-
trast, studies using islets from obese rats have demonstrated
that the blockade of CB1 receptor by rimonabant has a direct
effect on islets, reducing the basal insulin hypersecretion
due to obesity [85].
Mitochondrial Cannabinoid CB1 Receptor
Recently, several studies have demonstrated a role of CB1
receptors in mitochondrial biogenesis, suggesting that these
receptors may be a switch for mitochondrial activity that
may be the target of future therapies.
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CB1 receptors have been found in the mitochondria of
brain neurons, controlling cellular respiration and energy
production [86•]. While activation of these receptors
decreases respiration through a cAMP receptor mechanism
contributing to the control of neurotransmitter release, their
blockade may have the opposite effect.
They are also found in brown and white adipose tissues
or muscle. It is known that CB1 stimulation down-regulates
mitochondrial biogenesis and function in adipose tissue,
liver and skeletal muscle [87•]. In fact, diabetic/obese sub-
jects show an impaired mitochondrial biogenesis in meta-
bolically active tissues, likely due to the ECS overactivity
[88]. By contrast, in vitro studies have demonstrated that
rimonabant treatment promotes mitochondrial biogenesis in
adipocytes by inducing the expression of the endothelial
nitric oxide synthase (eNOS) [89]. Similarly, CB1 knockout
mice display an increased mitochondrial biogenesis and
eNOS expression compared to their wild-type littermates.
Therefore, rimonabant is able to restore the down-regulation
of mitochondrial biogenesis observed in adipocytes of mice
fed a high-fat diet to normal levels, preventing the increase
of body weight and adiposity [89]. Interestingly, a recent
study with immortalized murine adipocytes has reported that
CB1 inhibition directly promotes transdifferentiation of
white adipocytes into a mitochondrial-rich brown fat phe-
notype, and therefore these actions on thermogenesis and
insulin sensitivity may contribute to body weight loss and
improve glucose homeostasis [90•].
Rimonabant in Clinical Trials
The effects of rimonabant have been extensively explored in
humans through numerous clinical studies. In particular,
overweight and obese patients have been included in the
different Rimonabant in Obesity programs (RIO-Europe,
RIO-Lipids, RIO-North America, RIO-Diabetes and RIO-
Asia), displaying a significant body weight loss, waist cir-
cumference reduction and an improvement of cardiovascu-
lar risk factors at the end of these clinical trials with no
differences between Caucasian and Asian ethnic groups
[91–95]. Rimonabant reached the market after successful
trials revealing both metabolic benefits and body weight
reduction in overweight and obese subjects [91, 92]. How-
ever, chronic treatment with rimonabant increases the ap-
pearance of psychiatric adverse events, such as depressive
mood disorders and anxiety, increasing the risk of suicide
[96, 97]. Patients given rimonabant also show other adverse
reactions, including nausea and dizziness. Similarly, previ-
ous studies in animals had reported that acute administration
of rimonabant induces anxiety-like responses [98]. Due to
the appearance of these adverse effects, rimonabant has been
withdrawn from the market.
Is Still a Cannabinoid Receptor Antagonist a Response
for Obesity?
From the above discussed scientific evidence, it is clear
that peripheral blockade of CB1 receptors may induce
metabolic advantages for complicated obesity. However,
a major goal is to avoid the unwanted central effects. The
main critic to previous studies was the lack of control of
the type of patients receiving treatment. The existence
of previous affective disorders or the appearance of
rimonabant-induced one was not controlled sufficiently.
Now, after rimonabant withdrawal, non-centrally acting
CB1 blockers would reach the clinic. Thus, the only op-
tion may be to exploit the peripheral blockade and this can
be achieved through the following options: peripheral
restricted antagonists that do not cross blood-brain barrier
and dual ligands or combinatorial therapies that exploit
synergies between CB1 antagonists/additional targets by
enhancing thermogenesis and blocking lipid mobilization
(Fig. 1).
Peripherally Restricted CB1 Receptor Antagonists
Since the psychiatric adverse effects observed in patients
treated with rimonabant are derived from central CB1 recep-
tor blockade, several new CB1 blockers with limited brain
penetration are being synthesized and characterized to pre-
vent adverse effects observed with rimonabant while main-
taining anti-obesity properties.
Jagerovic and colleagues synthesized and characterized
LH-21, a triazole derivative that acts as a neutral CB1 receptor
antagonist [99], although other authors have described it as a
weak CB1 receptor inverse agonist [100]. LH-21 displays a
different pharmacological profile in comparison with rimona-
bant [101, 102]. Acute administration of this compound
reduces food intake in fasted rats [101]. Similarly, subchronic
treatment causes hypophagia and reduces body weight gain in
obese rats, but with no metabolic effects [102, 103•]. LH-21 is
more efficacious as anti-obesity drug in obese rats exposed to
enriched-fat diet than in control rats, likely due to the dysre-
gulation and overactivation of the ECS associated to obesity
[103•]. Contrary to the metabolic benefits of rimonabant and
AM251, obese rats treated with LH-21 do not display an
improvement of the obesity-associated hepatic steatosis
[103•]. The poor penetration of LH-21 into the central nervous
system indicates that its anorectic effects are mainly mediated
by peripheral CB1 receptors located in gut sensory terminals
that control satiety [57], and also with cannabinoid receptors
located in metabolically relevant tissues [21, 104]. Addition-
ally, very high doses of LH-21 have been shown to have
effects in CB1 receptor knockout mice, suggesting alternative
targets for this compound [100]. A recent study has indicated
that the anti-obesity properties of LH-21 may be mediated
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through modulation of the lipogenic pathways in adipose
tissue [103•]. In adipocytes, LH-21 treatment also affects the
gene expression of leptin, reducing its transcription and im-
proving the leptin resistance associated to obesity [103•].
Another interesting compound is AM6545, a structurally
modified analog of rimonabant, which acts as a neutral CB1
receptor antagonist with relatively poor penetrability into
the brain [104]. This drug reduces food intake in animals
fed high-fat and high-carbohydrate diets, but it is less effec-
tive in reducing regular chow intake [105]. Due to its low
brain penetration, AM6545 does not affect behavioral
responses mediated by CB1 receptors in the brain, such as
catalepsy, hypomotility, hypothermia and anxiety-like
behaviors [46•]. AM6545 reduces body weight gain and
the adiposity index, improving the metabolic profile of
obese mice fed a high-fat diet in a food intake-independent
manner [104]. In fact, this drug has been reported to decrease
lipogenic and increase lipolytic gene expression in both liver
and adipose tissue. Moreover, AM6545 treatment reverses the
hepatic steatosis induced by high-fat diet, reducing liver tri-
glycerides and hepatocellular damage. By contrast, AM6545
has no effect on body weight and adiposity in ob/ob mice,
likely due to leptin signaling deficiency [104]. Finally,
AM6545 is also able to reduce food intake and body weight
gain in CB1 receptor knockout mice, indicating the existence
of other alternative pathways [106•].
URB447 is a pyrrole-derived compound with CB1 antag-
onist/ CB2 agonist properties and with reduced brain pene-
tration. This drug decreases food intake and body weight
gain in mice [107]. Recently, it has been reported that
systemic administration of URB447 reduces fat intake in
sham fed rats, supporting the anti-obesity properties of
cannabinoid signaling blockade in the gut [76•].
In the last years, other compounds with reduced brain
penetration have been described. For instance, JD-2114 and
JD-5006 are non-brain penetrant CB1 antagonists that
Fig. 1 Potential alternatives to rescue a cannabinoid-based therapy for complicated obesity. The main aim should be to keepmetabolic efficacy avoiding
psychiatric side effects
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reduce body weight gain and improve metabolic parameters
in obese mice maintained on a high-fat diet [108]. Son and
colleagues have characterized a new rimonabant derivative
acting peripherally and showing anti-obesity properties in
diet-induced obese mice [109]. Recently, Receveur and col-
leagues have described another CB1 receptor antagonist
with low brain penetration that reduces body weight gain
in obese mice, although some actions of this compound at
the central level should not be ruled out [110].
In summary, all these compounds with poor permeability
into the central nervous system are able to induce weight
loss without interfering with the neurobehavioral control of
appetite, suggesting the importance of peripheral CB1 re-
ceptor blockade as anti-obesity target.
Efficacy of Combined Therapy for Obesity
The development of combined therapies is a new alter-
native in the field of obesity research. These types of
therapy consist of the simultaneous use of at least two
drugs targeting different systems involved in the regu-
lation of feeding behavior and energy balance. One of
the major benefits is that the co-administration of drugs
may result in an additive or synergistic effect. Moreover, since
combined therapies use low doses (sometimes sub-effective
doses) of each compound, it is possible to minimize or avoid
the adverse effects [111]. Several studies have proved the anti-
obesity effects of low doses of CB1 receptor blockers when
they are co-administered with different anorexigenic drugs as
well as the blockade of orexigenic actions induced by other
compounds.
Ghrelin is an appetite-stimulating peptide produced by
the brain and gastrointestinal tract, mainly in the stomach
[112]. The hyperphagic effects of this peptide are primarily
through activation of the paraventricular and arcuate nuclei
in the hypothalamus, both of which are involved in the
control of appetite and energy balance [113]. Growing evi-
dence suggests a functional interaction between brain ghre-
lin and ECS in appetite regulation. Thus, it has been
demonstrated that intranuclear infusion of ghrelin into the
paraventricular nucleus increases the feeding response in
rats, an effect that is reversed by a non-effective, systemic
dose of rimonabant [61, 62]. Pharmacological blockade of
CB1 receptors also prevents the increase of 2-AG levels
induced by ghrelin in the hypothalamus of mice [63]. Ac-
cordingly, no effects of ghrelin are observed in CB1 knock-
out mice [63].
The endogenous opioid system plays an important role in
the control of food intake and so, the hyperphagic effects
induced by opioids are well known [114]. Growing evi-
dence suggests a cross-talk between the ECS and the en-
dogenous opioid system in the regulation of appetite.
Systemic and intra-hypothalamic injections of morphine
promote appetite and this effect is abolished by peripheral
administration of rimonabant [115]. A synergistic effect
following a simultaneous blockade of cannabinoid and opi-
oid receptors has also been described. Co-administration of
sub-effective doses of rimonabant and the opioid antagonist
naloxone decreases food intake in rats, enhancing the effects
of each compound when they are given alone [116, 117].
Similar synergistic effects on food intake have been ob-
served in mice given a combination of AM251 and the
opioid antagonist nalmefene [118].
Orexin A (also called hypocretin 1) is a neuropeptide
primarily involved in the stimulation of feeding. Direct
infusions of orexin A into the lateral hypothalamus increase
food intake in a dose-dependent manner [119]. Orexinergic
neurons can integrate both central and peripheral signals
regarding feeding and energy balance, interacting with other
neurotransmission systems, including leptin, neuropeptide
Y and ECS [120, 121]. Regarding this possible interaction
between orexin and endocannabinoid systems, a co-
expression of CB1 receptors and orexin receptor 1 in several
brain regions, including the lateral hypothalamus has been
described. [122], suggesting a cross-talk between both
receptors [60]. In this regard, Crespo and colleagues have
demonstrated that effective doses of rimonabant and sub-
effective doses block the orexigenic actions of orexin A,
indicating an interaction between both systems at hypotha-
lamic levels [123].
The serotonergic system is also involved in the control of
appetite and energy homeostasis. Systemic and intracerebral
administrations of serotonin agonists reduce food intake and
body weight [124, 125•]. A growing body of evidence
suggests an interaction between serotonin and endocannabi-
noid systems in the regulation of appetite. Several brain area
co-express serotonin and cannabinoid receptors [126].
Sibutramine, a serotonin- and noradrenalin-reuptake inhibi-
tor, inhibits appetite, promotes weight loss and increases
thermogenesis in brown adipose tissue [127, 128]. Besides,
the administration of this drug is also associated to undesir-
able side-effects [129]. By contrast to previous studies that
have reported an additive anti-obesity effect after co-
administration of rimonabant and the serotonin-releasing
compound D-fenfluramine [117] or synergistic interactions
with serotonin agonists [130], the co-treatment of rimona-
bant and Sibutramine does not result in a significant anti-
obesity effect [131•].
Oleoylethanolamide (OEA), a structurally AEA-related
lipid with non-cannabinoid properties, is a mediator of satiety
that exerts anorectic effects mainly through peripheral mech-
anisms [132]. Thus, a combinational therapy with OEA and
rimonabant was suggested to enhance their respective benefi-
cial actions as anti-obesity drugs. In this regard, previous
studies have described a synergistic effect of both compounds
to decrease appetite. A low, non-effective dose of rimonabant
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potentiates the inhibitory actions of OEA on feeding in food-
deprived rats [57, 133]. In obese Zucker rats, a subchronic
treatment with both drugs improves the separate effects of
rimonabant and OEA, resulting in a marked decrease on
feeding, body weight gain and serum lipid levels [133]. Ad-
ditionally, this combinational therapy reduces the hepatic
steatosis observed in obese rats, decreasing liver fat depots
and improving liver function [133]. A similar effect has been
observed with the combination of LH-21 and OEA [102].
Cholecystokinin (CCK) is another peripheral hormone
that acts as a satiety factor, mainly through CCK1 receptors.
The co-localization of these receptors with the CB1 recep-
tors in peripheral nerve terminals of the gut, suggests an
interaction between both receptors. Recently, an additive
satiety induction has been reported in rats following the
co-administration of rimonabant and a CCK1 agonist [74•].
Development of Novel Dual Ligands
Although the traditional strategy in medicinal chemistry of
one disease /one target is still valid, the idea of a multi-
target approach is gradually gaining interest especially in
the case of complex diseases such as obesity as has already
been mentioned. Some recent examples include combined
administration of rimonabant and orlistat [134], and rimo-
nabant and the melanin concentrating hormone antagonist
SNAP-94847 [135•].
However, a different strategy is to design a compound with
two pharmacophoric groups capable of interacting simulta-
neously with two different biological targets. These are the so-
called designed multiple ligands which are being the subject
of intense research in different therapeutic areas [136].
In this context, fatty acid amides of aryl pyrazoles, related
to rimonabant and OEA, have been synthesized as dual
CB1/ PPARα ligands. Although the compounds did not
show significant cannabinoid properties certain derivatives
were able to reduce food intake in rats, some through
PPARα activation and others through an unknown mecha-
nism [137]. More recently, rimonabant has been fused to
fibrate resulting in compounds with nanomolar affinity for
both cannabinoid and PPARα receptors, one of them being
CB1 selective [138•].
Taking into account the complexity of obesity and eating
disorders, DML´s can be considered an interesting approach
although there is still considerable research to be done in
this field.
Conclusions
The clinical experience with the cannabinoid CB1 receptor
blocker rimonabant revealed the benefits of blocking can-
nabinoid receptors in complicated obesity. It also indicated
that central effects on affective behaviors would be the limit
for its therapeutic use. Targeting the peripheral cannabinoid
receptors with antagonists that do not cross the blood-brain
barrier might be an alternative for exploiting the benefits
derived of reducing the impact of the overactive endocanna-
binoid system in obesity. Alternatives may derive of exploit-
ing peripheral synergies such as those derived of simultaneous
target of cannabinoid CB1 receptors and either PPARα recep-
tors of peptide receptors such as CCK or ghrelin receptors.
Synergism means greater efficacy at doses devoid of unwant-
ed central effects, offering tissue specificity (depending on
target expression and the combination of drugs selected).With
these premises, a second opportunity for cannabinoid receptor
antagonism might be set in place for complicated obesity.
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